Showing results (31-40 of 44) with videos related to
Sort By:
Pageof 5
Nature|October 2, 2024
LYCHOS is a human hybrid of a plant-like PIN transporter and a GPCRCharles Bayly-Jones, Christopher J Lupton, Alastair C Keen, et al.Proceedings of the National Academy of Sciences of the United States of America|December 3, 2015
Stonefish toxin defines an ancient branch of the perforin-like superfamilyAndrew M Ellisdon, Cyril F Reboul, Santosh Panjikar, et al.Science Signaling|May 5, 2021
Structural analysis of the PTEN:P-Rex2 signaling complex reveals how cancer-associated mutations coordinate to hyperactivate Rac1Laura D'Andrea, Christina M Lucato, Elsa A Marquez, et al.Science Immunology|August 8, 2017
Homodimerization attenuates the anti-inflammatory activity of interleukin-37Andrew M Ellisdon, Claudia A Nold-Petry, Laura D'Andrea, et al.Cell|January 9, 2026
Structure of the lysosomal KICSTOR-GATOR1-SAMTOR nutrient-sensing supercomplexChristopher J Lupton, Charles Bayly-Jones, Shuqi Dong, et al.Cell Reports|March 30, 2017
Cell Traversal Activity Is Important for Plasmodium falciparum Liver Infection in Humanized MiceAnnie S P Yang, Matthew T O'Neill, Charlie Jennison, et al.Biorxiv : the Preprint Server for Biology|February 26, 2024
Feed-forward stimulation of CAMK2 by the oncogenic pseudokinase PEAK1 generates a therapeutically "actionable" signalling axis in triple negative breast cancerXue Yang, Xiuquan Ma, Tianyue Zhao, et al.Nature Communications|February 21, 2025
Activation of CAMK2 by pseudokinase PEAK1 represents a targetable pathway in triple negative breast cancerXue Yang, Xiuquan Ma, Tianyue Zhao, et al.Cell Chemical Biology|October 26, 2021
Protein engineering of a stable and potent anti-inflammatory IL-37-Fc fusion with enhanced therapeutic potentialAlexander Bujotzek, Georg Tiefenthaler, Laurent Lariviere, et al.Nature Immunology|March 3, 2015
IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transductionClaudia A Nold-Petry, Camden Y Lo, Ina Rudloff, et al.Pageof 5